AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02368197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel (Cardionovum Legflow drug eluting balloon)
Description: Elution of paclitaxel from inflated balloon catheter into vessel wall
Study NCT02368197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Balloon angioplasty (Bard Dorado)
Description: Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
Study NCT03295084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Dose Escalation
Study NCT03295084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Dose Escalation
Study NCT00913172 — intervention group
Intervention type: OTHER
Intervention: Treatment
Description: Directly observed treatment (DOT) by health extension workers (HEWs)
Study NCT02520622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital photographs loaded onto a mobile device
Study NCT02520622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Skin exam reminders
Study NCT02520622 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support network
Study NCT03609528 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CamPROBE
Description: To be completed
Study NCT00647530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Study NCT00647530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Study NCT00647530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study NCT00647530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00647530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00647530 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Study NCT00647530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00664430 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Calcitriol
Description: Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
Study NCT00664430 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paricalcitol
Description: Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
Study NCT03404583 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centred care at distance through an eHealth platform
Description: Person-centred care at distance through an eHealth platform, used by professionals, patients and relatives
Study NCT05437783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Dihydrate
Description: exclusively hospitalized at Bandarban Sadar hospital, Bandarban, Bangladesh. Participants will be fasting overnight for 10 h, all subjects will receive a single oral dose of 500mg of azithromycin with 250 ml of water. Drug intake will be ensured by direct supervision. Standardized meals will be served 4 and 10 h after dosing. Venous blood sample will be collected at multiple timepoints beginning before drug administration (0h) and containing at timepoints 1.0,2.0,3.0,4.0,6.0,8.0,12.0,24.0,48.0 and 72.0h post dosing. Two ml peripheral blood will be collected from each subject for genetic study.
Study NCT02876770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Melatonin
Description: Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
Study NCT02876770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
Study NCT02042729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2022- Current Formula Tape
Description: Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days.
Study NCT02042729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: E2022- New Formula Tape
Description: Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.~Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days.
Study NCT02042729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2022 Matching Placebo- Current Formula Tape
Study NCT03549520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur hexafluoride lipid-type A microspheres
Description: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg.
Study NCT02042729 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E2022 Matching Placebo- New Formula Tape
Study NCT02238496 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cytoreductive surgery
Description: Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
Study NCT02238496 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Perifosine
Description: Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
Study NCT03192436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
Study NCT02238496 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
Study NCT04474899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxonidine 0.4 MG
Description: Participants will be randomly assigned to receive moxonidine 0.4mg/daily and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
Study NCT04474899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg
Description: Participants will be randomly assigned to receive amlodipine 5mg and will later receive the alternate treatment. As the study is double blind neither the participant nor the study personnel will be aware of which treatment is currently being tested to avoid any effect this may have on the results. The two 12-week treatment phases will be separated by a 6-week wash out (drug-free) period.
Study NCT01341652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pTVG-HP
Description: pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
Study NCT01341652 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rhGM-CSF
Description: rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
Study NCT03192436 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: Low-intensity (Ispta \< 720 mW/cm2, Isppa \< 190 W/cm2) transcranial focused ultrasound
Study NCT01889914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 different procedures of administration of insulin
Description: Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
Study NCT03624725 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified BII+Braun
Description: modified BII+Braun digestive tract reconstruction
Study NCT00966108 — intervention group
Intervention type: DEVICE
Intervention: SENSIMED Triggerfish
Description: Ocular Telemetry Sensor for IOP monitoring
Study NCT00806585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-0736
Study NCT00806585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0736
Study NCT00806585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Study NCT00806585 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: HCTZ
Study NCT01103414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoglitazone
Description: 50 mg capsules, once daily for 84 days
Study NCT01103414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoglitazone
Description: Mitoglitazone 100 mg capsules, once daily for 84 days
Study NCT01103414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoglitazone
Description: Mitoglitazone 150 mg capsules, once daily for 84 days
Study NCT00115804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
Study NCT04129606 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computed tomographic cystography
Description: CT cystogram performed after the procedure by the injection of 400mL of 1/4 saline-diluted contrast solution (meglumine ioxitalamate) with low-pressure infusion (60 cm gravity pressure) through the Foley catheter.
Study NCT03766334 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Highland Barley Diet
Description: Highland Barley Diet(20g, thrice-daily)
Study NCT01103414 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone 45 mg, once daily for 84 days
Study NCT01103414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily for 84 days
Study NCT02297334 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb device
Description: In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
Study NCT04103255 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High frequency and intensive prevention program
Description: This study is a 4 week non-randomized controlled trial (RCT)
Study NCT04103255 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High frequency and intensive prevention program
Description: This study is a 4 week non-randomized controlled trial (RCT)
Study NCT04209647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REHIT Exercise
Description: -Start with warm-up period --> %50 of maximum work rate, 3 minutes~One Exercise Cycle consists of:~* 15 seconds exercise period: %100 of maximum work rate~* 15 seconds recovery period: %50 of maximum work rate~Total Duration: 10 minutes
Study NCT04209647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Aerobic Exercise
Description: At %50 of maximum heart rate, 30-60 minutes aerobic exercise
Study NCT00233259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Mediterranean dietary program
Study NCT00233259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Physical activity program
Study NCT00233259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management
Description: Stress management program
Study NCT00233259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Support
Description: Social support
Study NCT00233259 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation
Description: Smoking cessation program
Study NCT00637910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
Study NCT00637910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
Study NCT02825108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra uterine injection of tissue culture medium containing HCG+ET
Description: 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
Study NCT00233259 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Usual Diabetes Care Control group
Study NCT02430662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
Study NCT02825108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra uterine injection of tissue culture medium +ET
Description: ) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
Study NCT02825108 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ET
Description: the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
Study NCT02006927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve Stimulation
Description: Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
Study NCT02621892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Study NCT02621892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02920320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based self-help program
Study NCT01358162 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given orally, daily for 14 consecutive days
Study NCT01358162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SQ109
Description: A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
Study NCT01217034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE with sorafenib
Description: Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
Study NCT01217034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE alone
Description: TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
Study NCT05239078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: local anaesthetic injection
Description: Inferior alveolar nerve block
Study NCT05239078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Inferior alveolar nerve block
Study NCT02430662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT02059213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrance
Study NCT02059213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Study NCT02059213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Study NCT02059213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoladex
Study NCT02059213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Study NCT02059213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupron Depot
Study NCT02059213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupron Depot
Study NCT02242825 — intervention group
Intervention type: DRUG
Intervention: Micardis®
Study NCT02242825 — intervention group
Intervention type: DRUG
Intervention: MicardisPlus®
Study NCT00673920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral or parenteral repeating dose
Study NCT00673920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral or parenteral repeating dose
Study NCT00673920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab was administered as a slow intravenous (iv) infusion during each course as either 200 mg on Day 1 and Day 15 (OCR 200×2) or as 400 mg given on Day 1 (OCR 400×1).~Ocrelizumab was administered in combination with Methotrexate.
Study NCT00358917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 800/200 mg once-daily (QD) tablet
Study NCT00358917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
Description: LPV/r 400/100 mg twice-daily (BID) tablet
Study NCT00062114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00062114 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Study NCT00568958 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS counseling
Description: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
Study NCT00568958 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: BASICS counseling
Description: Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
Study NCT00673920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study NCT00673920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous repeating dose
Study NCT01071161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: azithromycin, tablets, during 12 weeks, three times a week, 250mg
Study NCT00568958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
Study NCT01071161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00285051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inhaled delta-8-THC 300mcg or 600mcg per dose
Description: drugs to be used to prevent/treat nausea and/or vomiting due to cancer chemotherapy drug Patients will receive chemotherapy on day 0 and receive study medication, return on day 1or 2 and again on day 4 to return medication. There will be at least 10 days between the last dose of study medication from the first cycle and the first dose for the 2nd cycle..~Patients will receive for each chemotherapy cycle either IV Ondansetron and Placebo inhalation, or IV Placebo and delta-8-THC inhalation. The patients will be randomized to receive one of 2 doses of the THC, either 300mcg or THC or 600mcg of THC
Study NCT03641196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed appliance
Description: Use of a cemented modified palatal Nance appliance presenting a bite-plane
Study NCT03641196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Composite bite plane
Description: treatment with a composite build up in the palatal aspect of the upper central incisors.
Study NCT00085527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: depsipeptide
Study NCT01924780 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stimulation 10 minutes
Description: NEMOS transvagal stimuli 10 minutes